Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer

Clinical Cancer Research

Volumn 13, Issue 21, 2007, Pages 6257-6266

  Gibcus, Johan H ^a   Menkema, Lorian ^a   Mastik, Mirjam F ^a   Hermsen, Mario A ^b   De Bock, Geertruida H ^a   Van Velthuysen, Marie Louise F ^c   Takes, Robert P ^d   Kok, Klaas ^a   Alvarez Marcos, Cesar A ^b   Van Der Laan, Bernard F A M ^a   Van Den Brekel, Michiel W M ^c   Langendijk, Johannes A ^a   Kluin, Philip M ^a   Van Der Wal, Jacqueline E ^a   Schuuring, Ed ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ASSOCIATED DEATH DOMAIN PROTEIN; ISOPROTEIN; PACLITAXEL; SERINE;

ADULT; AGED; AMPLICON; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE REGULATION; CHROMOSOME 11Q; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORTACTIN GENE; CYCLIN D1 GENE; DISEASE SPECIFIC SURVIVAL; FADD GENE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MAPPING; GENE OVEREXPRESSION; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LARYNX CANCER; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PATIENT SELECTION; PHARYNX CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CELL CYCLE; CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 11; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GENE EXPRESSION PROFILING; HUMANS; LARYNGEAL NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; PACLITAXEL; PHARYNGEAL NEOPLASMS; PHOSPHORYLATION; TIME FACTORS;

EID: 35948938574     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1247     Document Type: Article

References (50)

1. Nix PA, Greenman J, Cawkwell L, Stafford ND. Defining the criteria for radioresistant laryngeal cancer. Clin Otolaryngol Allied Sci 2004;29:705-8.
2. Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist 2005;10:215-24.
3. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
4. Albertson DG. Gene amplification in cancer. Trends Genet 2006;22:447-55.
5. Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006;24:2376-85.
6. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene 1995;159:83-96.
7. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003;78:323-35.
8. Akervall JA, Jin Y, Wennerberg JP, et al. Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer 1995;76:853-9.
9. Hermsen M, Alonso GM, Meijer G, et al. Chromosomal changes in relation to clinical outcome in larynx and pharynx squamous cell carcinoma. Cell Oncol 2005;27:191-8.
10. Rodrigo JP, Garcia LA, Ramos S, Lazo PS, Suarez C. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2000;6:3177-82.
11. Williams ME, Gaffey MJ, Weiss LM, Wilczynski SP, Schuuring E, Levine PA. Chromosome 11Q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1993;119:1238 - 43.
12. Lammie GA, Fantl V, Smith R, et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991;6:439-44.
13. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992;7:355-61.
14. Janssen JW, Cuny M, Orsetti B, et al. MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer. Int J Cancer 2002;102:608-14.
15. Huang X, Gollin SM, Raja S, Godfrey TE. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A 2002;99:11369-74.
16. Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523-35.
17. Freier K, Sticht C, Hofele C, et al. Recurrent coamplification of cytoskeleton-associated genes EMS1 and SHANK2 with CCND1 in oral squamous cell carcinoma. Genes Chromosomes Cancer 2006;45:118-25.
18. Luo ML, Shen XM, Zhang Y, et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 2006;66:11690-9.
19. van Rossum AG, Moolenaar WH, Schuuring E. Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 2006;312:1658-70.
20. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 2001;20:6418-34.
21. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-11.
22. Veltman JA, Schoenmakers EF, Eussen BH, et al. High-throughput analysis of subtelomeric chromosome rearrangements by use of array-based comparative genomic hybridization. Am J Hum Genet 2002;70:1269-76.
23. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144-6.
24. Watson JE, Doggett NA, Albertson DG, et al. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 2004;23:3487-94.
25. Gibcus JH, Kok K, Menkema L, et al. High-resolution mapping identifies a commonly amplified 11q13.3 region containingmultiple genes flanked by segmental duplications. Hum Genet 2007;121:187-201.
26. Hermsen M, Guervos MA, Meijer G, et al. New chromosomal regions with high-level amplifications in squamous cell carcinomas of the larynx and pharynx, identified by comparative genomic hybridization. JPathol 2001;194:177-82.
27. Takes RP, Baatenburg deJong RJ, Schuuring E, et al. Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 1997;123:412-9.
28. Imoto I, Yang ZQ, Pimkhaokham A, et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 2001;61:6629-34.
29. Stark GR, Debatisse M, Giulotto E, Wahl GM. Recent progress in understanding mechanisms of mammalian DNA amplification. Cell 1989;57:901-8.
30. Chen G, Bhojani MS, Heaford AC, et al. Phosphorylated FADD induces NF-κB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A 2005;102:12507-12.
31. Bhojani MS, Chen G, Ross BD, Beer DG, Rehemtulla A. Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle 2005;4:1478-81.
32. Jarvinen AK, Autio R, Haapa-Paananen S, et al. Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. Oncogene 2006;25:6997-7008.
33. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71.
34. van Rossum AG, de Graaf JH, Schuuring-Scholtes E, et al. Alternative splicing of the actin binding domain of human cortactin affects cellmigration. J Biol Chem 2003;278:45672-9.
35. Serra-Pages C, Kedersha NL, Fazikas L, Medley Q, Debant A, Streuli M. The LAR transmembrane protein tyrosine phosphatase and a coiled-coil LAR-interacting protein co-localize at focal adhesions. EMBO J 1995;14:2827-38.
36. Heidenblad M, Lindgren D, Veltman JA, et al. Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic implications. Oncogene 2005;24:1794-801.
37. Monni O, Barlund M, Mousses S, et al. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci U S A 2001;98:5711-6.
38. Cromer A, Carles A, Millon R, et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 2004;23:2484-98.
39. Patel AS, Schechter GL, Wasilenko WJ, Somers KD. Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene 1998;16:3227-32.
40. Alappat EC, Volkland J, Peter ME. Cell cycle effects by C-FADD depend on its C-terminal phosphorylation site. J Biol Chem 2003;278:41585-8.
41. Izzo JG, Papadimitrakopoulou VA, Li XQ, et al. Dysregulated cyclin D1expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene 1998;17:2313-22.
42. Tibbetts MD, Zheng L, Lenardo MJ. The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol 2003;4:404-9.
43. Park SM, Schickel R, Peter ME. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol 2005;17:610-6.
44. Osborn SL, Sohn SJ, Winoto A. Constitutive phosphorylation mutation in FADD results in early cell cycle defects. J Biol Chem 2007;282:22786-92.
45. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Kishi M, Konishi N. Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. Carcinogenesis 2004;25:1089-97.
46. Gomez-Angelats M, Cidlowski JA. Molecular evidence for the nuclear localization of FADD. Cell Death Differ 2003;10:791-7.
47. Alappat EC, Feig C, Boyerinas B, et al. Phosphorylation of FADD at serine 194 by CKIα regulates its non-apoptotic activities. Mol Cell 2005;19:321-32.
48. Matsuyoshi S, Shimada K, Nakamura M, Ishida E, Konishi N. FADD phosphorylation is critical for cell cycle regulation in breast cancer cells. Br J Cancer 2006;94:532-9.
49. Scaffidi C, Volkland J, Blomberg I, Hoffmann I, Krammer PH, Peter ME. Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J Immunol 2000;164:1236-42.
50. Gupta N, Hu LJ, Deen DF. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Radiat Oncol Biol Phys1997;37:885-95.